Suppr超能文献

迷走神经阻滞剂和β肾上腺素能药物在非免疫性和过敏性哮喘鉴别诊断中的连续效应

Successive effects of a vagolitic and a betadrenergic in the differential diagnosis of nonimmunologic and allergic asthma.

作者信息

Mathov E, Jares D M

出版信息

Allergol Immunopathol (Madr). 1984 Jul-Aug;12(4):293-302.

PMID:6239524
Abstract

In order to determine whether the vagal mechanism is predominant in the physiopathology of asthma, we investigated in the first part of this work. If the new vagolithic, ipratropium can improved the respiratory parameters of asthmatic patients. If the effect is complete or admits yet the supplementary effect of a betadrenergic, Fenoterol. 46 asthmatic patients were registered in some spirographic parameters, e.g. FEV1 (Forced Expiratory Volume in 1 sec.), MMFR25-75 (Maximum Mid-expiratory Flow Rate between the 25 per cent and the 75 per cent of the forced vital capacity) and FEF 200-1200 (Forced Expiratory Flow between 200 ml. and 1200 ml. of the forced vital capacity). The same registers were made 30 minutes after aerolization with 0.05 mg of Ipratropium (two shots) and 10 minutes after 60 micrograms of Fenoterol (three shots). It was found that 78.5 per cent of the patients improved one of the parameters with Ipratropium more than 20 per cent. But 58 per cent of the patients showed an additional improvement with the betadrenergic in one or more of the parameters. This shows that in many cases the physiopathology of asthma is mixed, vagal and betareceptor dependent, in which the medication with Ipratropium plus Fenoterol will obtain better results. Only in some patients the bronchial spasm is vagolithic dependent exclusively, while few others responded to betadrenergic and only 9 per cent of patients did not respond to either one. In the second part of this work we tried to verify if by anamnestic inquiry and additional use of Ipratropium and Fenoterol it is possible to recognize one group of patients with asthma produced by nonimmunologic irritant factors acting on the large airways from another group with asthma due to inhalants allergens and spasm of the small bronchi. The same 46 patients were divided in two groups: Patients who recognize that asthmatic accesses begin after exercise, laughter cold weather, cigarette smoker exposure sprays, synthetics and insecticides. This is the predominantly irritative nonimmunologic group. Patients who recognize that coughing or wheezing begins after contact either with pollen, dust or danders. This is the predominantly allergic group. We proved that patients A improve more with Ipratropium and the opposite is true with patients B. The results with the two drugs are roughly parallel to the anamnestic records.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

为了确定迷走神经机制在哮喘病理生理学中是否占主导地位,我们在这项研究的第一部分进行了调查。即新的迷走神经阻断剂异丙托溴铵是否能改善哮喘患者的呼吸参数。其效果是完全的,还是仍有β肾上腺素能药物非诺特罗的补充作用。46名哮喘患者记录了一些肺功能参数,如一秒用力呼气量(FEV1)、25%至75%用力肺活量之间的最大呼气中期流速(MMFR25 - 75)以及200毫升至1200毫升用力肺活量之间的用力呼气流量(FEF 200 - 1200)。在用0.05毫克异丙托溴铵雾化(两次喷雾)后30分钟以及60微克非诺特罗(三次喷雾)后10分钟进行了同样的记录。结果发现,78.5%的患者使用异丙托溴铵后其中一项参数改善超过20%。但58%的患者在一项或多项参数上使用β肾上腺素能药物后有额外改善。这表明在许多情况下,哮喘的病理生理学是混合的,依赖迷走神经和β受体,其中使用异丙托溴铵加非诺特罗的药物治疗会取得更好的效果。只有一些患者的支气管痉挛仅依赖迷走神经阻断,而其他少数患者对β肾上腺素能药物有反应,只有9%的患者对两者均无反应。在这项研究的第二部分,我们试图通过问诊以及额外使用异丙托溴铵和非诺特罗来验证,是否有可能从另一组由吸入性过敏原和小支气管痉挛引起哮喘的患者中识别出一组由作用于大气道的非免疫性刺激因素导致哮喘的患者。同样的46名患者被分为两组:一组患者承认哮喘发作始于运动、大笑、寒冷天气、接触香烟烟雾、喷雾剂、合成物和杀虫剂后,这是主要由刺激性非免疫因素导致的组;另一组患者承认咳嗽或喘息始于接触花粉、灰尘或皮屑后,这是主要由过敏因素导致的组。我们证明A组患者使用异丙托溴铵后改善更明显,而B组患者则相反。两种药物的结果与问诊记录大致相符。(摘要截断于400字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验